JNJ Stock Keeps Climbing. Should You Climb On?

This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.

Johnson & Johnson (JNJ) develops and sells a vast portfolio of pharmaceuticals and medical devices, from cancer therapies to surgical tools. The market has taken notice of its execution, bidding the stock up over 71% in the last year, far outpacing the S&P 500. Now trading just 3% shy of its 52-week high, the stock has clear momentum. The run is real; the open question for any would-be buyer is whether there is anything left to gain at this price.

This Run Is Fueled by More Than Just a Strong Market

JNJ’s performance is driven by more than a market updraft. The company’s operating margin over the last twelve months is 27%, well above the 18.4% median for the S&P 500. Revenue growth is also a touch ahead of the market, at 7.9% versus the median 7.5%.

This financial strength comes from a business firing on multiple cylinders. Management is confident enough to project a “line of sight to double-digit growth by the end of the decade.” The engine for that growth is what they call the “strongest portfolio pipeline in the history of Johnson & Johnson,” with key new drugs in oncology and immunology.

A prime example is ICOTYDE, a new oral treatment for plaque psoriasis. The company believes it “has the potential to be one of our largest products ever.” Rather than being a future hope, this is a core part of the story the market is buying today.

But Does the Price Tag Already Demand a Perfect Race?

The ticket for this quality is not cheap. JNJ trades at a price-to-earnings multiple of 29.7, a clear premium to the S&P 500 median of 24.4. The price-to-sales multiple tells a similar story: 6.5 for JNJ versus 3.3 for the market median. The market is already charging for excellence.

The question of why some stocks seem to hold up against broader market volatility is a persistent one. A recent analysis, for instance, looked into why JNJ stock has been defying the market’s daily mood swings.

The honest catch lies in the company’s MedTech division. While the segment grew, its Surgery business posted growth of just 1.2% in the latest quarter. Management acknowledged “competitive pressures in energy and endocutters” as a factor. A slowdown in a major division is the kind of stumble that can test a premium valuation. For investors who prefer to bet on the entire healthcare sector rather than a single name, a broad healthcare ETF like XLV can offer diversified exposure.

The Tell Is How Quickly a New Drug Can Pick Up the Baton.

For Johnson & Johnson, the path forward depends on its new products outrunning any weakness in its established ones. The company is navigating a significant “headwind from STELARA,” its blockbuster immunology drug now facing biosimilar competition.

This puts the spotlight squarely on the launch of ICOTYDE. Management reported that shortly after approval, prescriptions had been written for “about 1,500 patients.” The critical test for investors is how quickly that initial interest converts into a powerful revenue stream, proving the pipeline can indeed replace and grow beyond its legacy blockbusters. That ramp will determine if this runner still has another lap in it.

For more runs powered by rising forecasts rather than pure sentiment, our Guidance Momentum screen surfaces exactly those setups, daily.

Winners Have A Way Of Taking Over Portfolios

A quality stock in a real uptrend is exactly the kind of position that quietly grows into most of your wealth – and the same momentum that built the gain can reverse it. Trimming the winner the usual way hands a chunk of those gains to the IRS. There is a way to lock in the gains and diversify without the tax hit.